CD8A and neoplasm: Cytotoxic CD4+ T cells have also been shown to contribute to durable immune checkpoint blockade responses in NSCLC patients by directly killing HLA-II-expressing tumor cells and augmenting HLA-I-dependent cytotoxic CD8+ T cell anti-tumor responses [39].